NEW YORK, Nov. 14, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced financial results for the third quarter ended September 30, 2023, and provided a corporate update.
"We have continued to make tangible progress on the clinical development of our lead asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838). Of particular importance, we completed enrollment of our phase 2 CALLIPER trial in patients with progressive multiple sclerosis (PMS) and most recently reported a stronger than expected, positive interim biomarker analysis of this trial. Notably, the clear separation observed in serum neurofilament light chain (NfL) over placebo in this patient population represents another key milestone for what could potentially be a first-in-class Nurr1 activator for PMS," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic. "Serum NfL responses were consistently observed for vidofludimus calcium across progressive MS disease as well as all subpopulations and even in non-active SPMS, a population where the medical need for new therapies is particularly high. We believe that the data set provides biomarker evidence that vidofludimus calcium's activity extends beyond the previously observed anti-inflammatory effects, further reinforcing its neuroprotective potential and bolstering our view that it may be associated with the reduced disability-worsening events we already observed in multiple sclerosis (MS) patients."
"Assuming that the top-line CALLIPER data, which we plan to report in April 2025, continues to show a neuroprotective effect, we may be able to position vidofludimus calcium as the first oral treatment for non-active secondary progressive MS. We also think that the drug's potential first-in-class ability to activate Nurr1 may meaningfully benefit our ongoing phase 3 ENSURE program in relapsing MS (RMS). To that end, we continue to enroll patients in our twin phase 3 ENSURE trials and currently expect to report an interim futility analysis in late 2024, with the read-out of the first of the ENSURE trials expected at the end of 2025. If ultimately approved, we continue to believe that vidofludimus calcium, with combined neuroprotective, anti-inflammatory, and antiviral effects, could potentially offer a unique treatment option targeted to the complex pathophysiology of MS."
Dr. Vitt continued, "In October and November, respectively, we presented the previously reported positive results from our phase 1b clinical trial of our second key program, IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6 (Sirtuin 6), in patients with celiac disease, at two prestigious medical conferences. The results, gathered during periods of gluten-free diet and gluten challenge, demonstrated positive effects for IMU-856 over placebo in four key dimensions of celiac disease pathophysiology: protection of the gut architecture, improvement of patients' symptoms, biomarker response and enhancement of nutrient absorption. IMU-856 was also observed to be safe and well-tolerated in this trial. We believe that this highly encouraging data provides initial clinical proof-of-concept for a potential new therapeutic approach to gastrointestinal disorders by promoting regeneration of bowel architecture. That said, we are currently preparing for clinical phase 2 testing of IMU-856 in ongoing active celiac disease (OACD), while also considering further potential clinical applications in other gastrointestinal disorders."
Third Quarter 2023 and Subsequent Highlights
Anticipated Clinical Milestones
Financial and Operating Results
Webcast Information
Immunic will host a webcast today at 8:00 am ET. To participate in the webcast, please register in advance by clicking here or on the "Events and Presentations" section of Immunic's website at: ir.imux.com/events-and-presentations. Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.
An archived replay of the webcast will be available approximately one hour after completion on Immunic's website at: ir.imux.com/events-and-presentations.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2 clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis and moderate-to-severe ulcerative colitis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, where it is currently in preparations for a phase 2 clinical trial. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: www.imux.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic's development programs and the targeted diseases; the potential for Immunic's development programs to safely and effectively target diseases; preclinical and clinical data for Immunic's development programs; the timing of current and future clinical trials and anticipated clinical milestones; the nature, strategy and focus of the company and further updates with respect thereto; the development and commercial potential of any product candidates of the company; and the company's expected cash runway. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, increasing inflation, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on February 23, 2023, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.
Contact Information
Immunic, Inc.
Jessica Breu
Head of Investor Relations and Communications
+49 89 2080 477 09
This email address is being protected from spambots. You need JavaScript enabled to view it.
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
This email address is being protected from spambots. You need JavaScript enabled to view it.
US Media Contact
KOGS Communication
Edna Kaplan
+1 617 974 8659
This email address is being protected from spambots. You need JavaScript enabled to view it.
Financials
Immunic, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts) (Unaudited) | ||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||
2023 | 2022 | 2023 | 2022 | |||||
Operating expenses: | ||||||||
Research and development | $ 19,796 | $ 16,537 | $ 63,931 | $ 50,520 | ||||
General and administrative | 3,774 | 3,579 | 11,911 | 11,641 | ||||
Total operating expenses | 23,570 | 20,116 | 75,842 | 62,161 | ||||
Loss from operations | (23,570) | (20,116) | (75,842) | (62,161) | ||||
Other income (expense): | ||||||||
Interest income | 766 | 230 | 2,534 | 343 | ||||
Other income (expense), net | 35 | (1,338) | 1,268 | (2,115) | ||||
Total other income (expense) | 801 | (1,108) | 3,802 | (1,772) | ||||
Net loss | $ (22,769) | $ (21,224) | $ (72,040) | $ (63,933) | ||||
Net loss per share, basic and diluted | $ (0.51) | $ (0.69) | $ (1.63) | $ (2.16) | ||||
Weighted-average common shares outstanding, basic and diluted | 44,574,377 | 30,564,995 | 44,227,264 | 29,655,946 | ||||
Immunic, Inc. Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts) (Unaudited) | |||
September 30, | December 31, | ||
(Unaudited) | |||
Assets | |||
Current assets: | |||
Cash and cash equivalents | $ 59,689 | $ 106,745 | |
Investments - other | — | 9,629 | |
Other current assets and prepaid expenses | 5,545 | 9,490 | |
Total current assets | 65,234 | 125,864 | |
Property and equipment, net | 288 | 294 | |
Right-of-use assets, net | 1,412 | 1,552 | |
Other long-term assets | 43 | 43 | |
Total assets | $ 66,977 | $ 127,753 | |
Liabilities and Stockholders' Equity | |||
Current liabilities: | |||
Accounts payable | $ 3,199 | $ 4,281 | |
Accrued expenses | 13,659 | 7,986 | |
Other current liabilities | 923 | 810 | |
Total current liabilities | 17,781 | 13,077 | |
Long term liabilities | |||
Operating lease liabilities | 789 | 992 | |
Total long-term liabilities | 789 | 992 | |
Total liabilities | 18,570 | 14,069 | |
Commitments and contingencies | |||
Stockholders' equity: | |||
Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding at September 30, 2023 and December 31, 2022 | — | — | |
Common stock, $0.0001 par value; 130,000,000 shares authorized and 44,595,383 and 39,307,286 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively | 4 | 4 | |
Additional paid-in capital | 433,818 | 427,925 | |
Accumulated other comprehensive income | 3,905 | 3,035 | |
Accumulated deficit | (389,320) | (317,280) | |
Total stockholders' equity | 48,407 | 113,684 | |
Total liabilities and stockholders' equity | $ 66,977 | $ 127,753 | |
| Last Trade: | US$1.10 |
| Daily Change: | -0.01 -0.90 |
| Daily Volume: | 796,675 |
| Market Cap: | US$99.090M |
November 13, 2024 November 07, 2024 October 22, 2024 September 18, 2024 September 04, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
